RACER: Regional Anesthesia for Cardiothoracic Enhanced Recovery

Sponsor
Stanford University (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT03781440
Collaborator
(none)
60
1
2
33.9
1.8

Study Details

Study Description

Brief Summary

The erector spinae plane block (ESPB) is a novel regional analgesic technique that provides pain relief with a peripheral nerve block catheter. The goal of this study is to see if bilateral ESPB catheters can improve clinical outcomes in patients undergoing cardiac surgery via sternotomy, such as decreasing the duration of postoperative mechanical ventilation, need for intravenous opioid medications, length of stay in the intensive care unit (ICU), and improving pain scores.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Bilateral ESP catheter with lidocaine
  • Procedure: Bilateral ESP catheter with saline
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Care Provider)
Primary Purpose:
Treatment
Official Title:
Regional Anesthesia for Cardiothoracic Enhanced Recovery for Patients Undergoing Cardiac Surgery Via Sternotomy
Actual Study Start Date :
Jan 1, 2020
Actual Primary Completion Date :
Sep 30, 2021
Anticipated Study Completion Date :
Oct 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Bilateral ESP catheter with Lidocaine

All participants will get the Erector Spinae Plane (ESP) catheters. Prior to transfer to the operating room, participants will receive bilateral ESP catheters at T7 level under ultrasound guidance. This arm is the treatment group and will receive lidocaine via alternating side automated infusion pump bolus dosing, continued until chest tube removal or postoperative day 5 (whichever occurs earliest).

Procedure: Bilateral ESP catheter with lidocaine
All participants will get the Erector Spinae Plane (ESP) catheters. Prior to transfer to the operating room, participants will receive bilateral ESP catheters at T7 level under ultrasound guidance. This arm is the treatment group and will receive lidocaine via alternating side automated infusion pump bolus dosing, continued until chest tube removal or postoperative day 5 (whichever occurs earliest).

Placebo Comparator: Bilateral ESP catheter with saline

All participants will get the Erector Spinae Plane (ESP) catheters. This arm is the control group and will have normal saline administered via ESP catheters, continued until chest tube removal or postoperative day 5 (whichever occurs earliest).

Procedure: Bilateral ESP catheter with saline
All participants will get the Erector Spinae Plane (ESP) catheters. This arm is the control group and will have normal saline administered via ESP catheters, continued until chest tube removal or postoperative day 5 (whichever occurs earliest).

Outcome Measures

Primary Outcome Measures

  1. Opioid Consumption [Duration of postoperative recovery (typically 1-2 weeks)]

    IV and PO opioid requirements converted to morphine equivalent

Secondary Outcome Measures

  1. Delirium and agitation post-operatively [Duration of ICU stay (typically 2-5 days)]

    Richmond Agitation-Sedation Score from -5 to +4 (-5 is the most sedation, +4 is the least sedated.

  2. Determine post-operative pain scores [Duration of postoperative recovery (typically 1-2 weeks)]

    11-point numerical rating scale (NRS) from 0-10, 0 signifying no pain, 10 signifying the worse pain.

  3. Median time to extubation in patients with ESPB [Duration of postoperative recovery (typically 1-2 weeks)]

    duration in mechanical ventilation in hours

  4. Length of stay in hospital [Duration of postoperative recovery (typically 1-2 weeks)]

    number of post-operative days spent in hospital

  5. Length of stay in ICU [Duration of postoperative recovery (typically 1-2 weeks)]

    number of post-operative days spent in ICU

  6. Quality of recovery at 72 hours [post-operative day 3]

    Survey based (Quality of Recover 15) patient reported outcomes. There are 15 questions based on a scale of 0-10 per questions, 0 signifying the worst outcome, 10 signifying the best, for a score range of 0-150.

  7. Inflammatory biomarker analysis [First panel pre-incision; second panel 6hrs (+/-3hrs) post-procedure; third panel 24hrs (+/-3hrs) post-procedure; fourth panel 48hrs (+/-3hrs) post-procedure]

    Pro and anti-inflammatory biomarker panel at 4 time points perioperatively. We will be analyzing IL10 concentrations as an anti-inflammatory biomarker and IL6 and TN alpha as pro-inflammatory biomarkers in either a ELISA assay or Luminex.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Give consent to participate in study

  • planned sternotomy

  • specific procedures: CABG (coronary artery bypass grafting) or AVR (aortic valve repair or replacement) or MVR (mitral valve repair or replacement) or combination of any of 2 of these

  • Primary or first redo sternotomy

Exclusion Criteria:
  • Participants who cannot give consent

  • Patients who are clinically unstable or require urgent/emergent intervention

  • more than1 prior sternotomy

  • planned aortic arch procedures

  • preoperative coagulopathy (INR >1.5, PTT >35) or ongoing anticoagulation (heparin infusion, therapeutic low molecular weight heparin, warfarin, dual antiplatelet therapy)

  • Severe ventricular dysfunction (left or right ventricle)

  • Symptomatic heart failure (systolic or diastolic)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Stanford University Stanford California United States 94305

Sponsors and Collaborators

  • Stanford University

Investigators

  • Principal Investigator: Jessica Brodt, MD, Stanford University
  • Principal Investigator: Ban Tsui, MD, Stanford University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Chi-Ho Ban Tsui, Professor, Stanford University
ClinicalTrials.gov Identifier:
NCT03781440
Other Study ID Numbers:
  • 47647
First Posted:
Dec 19, 2018
Last Update Posted:
Jan 20, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 20, 2022